Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Christine Mateus"'
Autor:
Clélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, Julien Schmidt, Domenico Mallardo, Atmane Seck, Vahe Asvatourian, Lydie Cassard, Patrick Saulnier, Ludovic Lacroix, Paul-Louis Woerther, Aurore Vozy, Marie Naigeon, Laetitia Nebot-Bral, Mélanie Desbois, Ester Simeone, Christine Mateus, Lisa Boselli, Jonathan Grivel, Emilie Soularue, Patricia Lepage, Franck Carbonnel, Paolo Antonio Ascierto, Caroline Robert, Nathalie Chaput
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
The gut microbiota has been reported to regulate the efficacy of cancer therapy. Here, the authors show that short-chain fatty acids, which are generated through bacterial fermentation, increases immune tolerance leading to resistance to anti-CTLA-4
Externí odkaz:
https://doaj.org/article/1117fcdf2fd44e30b8bbaa1e829d3ecf
Autor:
Shensi Shen, Sara Faouzi, Amandine Bastide, Sylvain Martineau, Hélène Malka-Mahieu, Yu Fu, Xiaoxiao Sun, Christine Mateus, Emilie Routier, Severine Roy, Laurent Desaubry, Fabrice André, Alexander Eggermont, Alexandre David, Jean-Yves Scoazec, Stéphan Vagner, Caroline Robert
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Melanoma persister cells are tolerant to anti-BRAF and anti-MEK inhibition and can trigger cancer relapse. Here the authors show that a subset of N6-methyladenosine modified mRNAs is translationally activated in persister cells. This preferential tra
Externí odkaz:
https://doaj.org/article/e47491eb7c3744b2a9a1e54104826b8f
Autor:
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53745 (2013)
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimum
Externí odkaz:
https://doaj.org/article/1e9dff99dd604582ac2c2c7a3f9fad75
Publikováno v:
Bulletin du Cancer. 110:293-300
Autor:
Caroline POISSON, Christine MATEUS, Anda SAMPETREAN, Perrine RENARD, Florian SCOTTE, Benjamin VERRET, Jamila MARDAGHI, Sarah DAUCHY, Laurence VIGOURET-VIANT, Sarah DUMONT, François BLOT
Publikováno v:
Supportive Care in Cancer. 31
Purpose Collegial Support Meetings (CSM) have been set up in the Gustave Roussy Cancer hospital for inpatients whose complex care requires a multi-professional approachinvolving participants from various fields. CSMs are composed not only of oncologi
Autor:
Nicolas, Meyer, David, Pérol, Anne-Bénédicte, Duval-Modeste, Laïla, El Adaoui, Yoann, Lelarge, Ralph, Niarra, Christine, Mateus
Publikováno v:
Melanoma Research. 32:269-277
Cobimetinib combined with vemurafenib was available in France in 2015 through a 'Temporary Authorization for Use' program (TAU, preapproval access pending its marketing on 2016) for patients with v-raf murine sarcoma viral oncogene homolog B1-mutant
Autor:
Lluis M. Mir, Gerwin J. Puppels, Caroline Robert, Angelo Paci, Alexander M.M. Eggermont, Emilie Lanoy, Matthieu Texier, Vincent Noordhoek Hegt, Senada Koljenović, Gorana Tomasic, Nyam Kamsu Kom, Atmane Seck, David Planchard, Benjamin Besse, Emilie Routier, Christine Mateus, Céline Boutros, Séverine Roy, Tom C. Bakker Schut, Peter J. Caspers, Antoine Azan
Mean LD score for the validation data set for Stratum Corneum skin layer for MEK inhibitors (A), EGFR inhibitors (B) and BRAF inhibitors (C) and for Viable Epidermis skin layer for MEK inhibitors (D), EGFR inhibitors (E) and BRAF inhibitors (F). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ecd191e71b2feda7c9ec688f3b0137b
https://doi.org/10.1158/0008-5472.22415429.v1
https://doi.org/10.1158/0008-5472.22415429.v1
Autor:
Caroline Robert, Nicolas Dumaz, Alain Eychène, Stephan Vagner, Sabine Druillennec, Alexander M. Eggermont, Alain Spatz, Ludovic Lacroix, Lise Boussemart, Nyam Kamsu-Kom, Jocelyne André, Magalie Larcher, Alain Sarasin, David Malka, Jean-Charles Soria, Emilie Hollville, Janine Wechsler, Gorana Tomasic, Bernard Escudier, Christine Mateus, Jean Philippe Arnault
PDF file - 208K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b14c5740a026d255c8835730c846eba
https://doi.org/10.1158/1078-0432.22446047.v1
https://doi.org/10.1158/1078-0432.22446047.v1
Autor:
Caroline Robert, Nicolas Dumaz, Alain Eychène, Stephan Vagner, Sabine Druillennec, Alexander M. Eggermont, Alain Spatz, Ludovic Lacroix, Lise Boussemart, Nyam Kamsu-Kom, Jocelyne André, Magalie Larcher, Alain Sarasin, David Malka, Jean-Charles Soria, Emilie Hollville, Janine Wechsler, Gorana Tomasic, Bernard Escudier, Christine Mateus, Jean Philippe Arnault
Purpose: The emergence of skin tumors in patients treated with sorafenib or with more recent BRAF inhibitors is an intriguing and potentially serious event. We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b64f100253a531af17307af6e6bb76
https://doi.org/10.1158/1078-0432.c.6520631.v1
https://doi.org/10.1158/1078-0432.c.6520631.v1
Autor:
Caroline Robert, Stéphan Vagner, Julien Adam, Florent Grange, Andrea Cavalcanti, Alexander M. Eggermont, Ludovic Lacroix, Mélanie Laporte, Marie Breckler, Sandrine Agoussi, Gorana Tomasic, Marina Thomas, Nyam Kamsu-Kom, Margot Rubington, Emilie Routier, Christine Mateus, Hélène Malka-Mahieu, Isabelle Girault, Lise Boussemart
Vemurafenib-induced BRAF-CRAF dimerization (2 µM, 24h) detected by in situ PLA in SK-MEL2 cell line is not decreased by the adjunction of MEK inhibitor PD0325901 (1µM, 24h): each red dot represents a BRAF-CRAF heterodimer. The cells were countersta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ccde14792445797f1058e2a6b195597
https://doi.org/10.1158/0008-5472.22410666
https://doi.org/10.1158/0008-5472.22410666